Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Comfort to Those Suffering Chronic Pain & Inflammation

Ryan Allway, CFN Media
0 Comments| October 31, 2018



Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) latest innovation is “Comfort”, a nutraceutical designed to alleviate chronic pain and inflammation – the first in line of a dozen new products the company expects to launch over 36 months.

According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated “acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone. This includes the total incremental cost of healthcare in North America due to pain ranging between $261 to $300 billion and $297-$336 billion due to lost productivity (based on days of work missed, hours of work lost, and lower wages). Additionally, the number of deaths associated with nonsteroidal anti-inflammatory drugs and opioids commonly used to treat those with chronic pain and inflammation has risen steadily.”

Overall, much more needs to be done to meet the challenges of pain and increase the widespread awareness of it. Abattis Bioceuticals took this goal to heart and set to work, analyzing not only the symptoms, but the physiology behind acute and chronic pain. The result is Comfort.

 
Activating Cannabinoid Receptors

According to Dr. Brazos Minshew, MSc, ND and President of the Abattis Medical Advisory Board, chronic pain occurs when internal systems within the body break down and fail to produce important chemicals necessary for regulating pain. This is because when our bodies experience severe, sustained pain, the ability to produce the endocannabinoids and endorphins which reduce our perception of pain slows and eventually stops altogether, resulting in the condition commonly referred to as chronic pain.

One of the body’s key pain management systems works through the production of bioactive lipids known as endocannabinoids which bind to and activate the CB-1 and CB-2, our body’s main cannabinoid receptors. When activated, the CB-1 and CB-2 modulate neural activity, helping our bodies cope with pain without becoming overwhelmed.

Comfort, Abattis’ proprietary nutraceutical – a pharmaceutical-grade, standardized nutrient – naturally stimulates the endocannabinoid system and the production of endorphins using ingredients such as Alpinia Galangal, a rare phytocannabinoid from the Ginger family, typically found in Indonesia and Malaysia, as well as Capsicum Annuum, which derives from the Pepper family, both of which have long been regarded for their medicinal properties. Alpinia Galangal  in particular, has been historically used to treat a range of ailments including gastrointestinal distress, and more recently, it’s been used to improve mental alertness, as an ingredient in cancer treatments, to reduce pain and inflammation, in addition to improving mobility. The company has secured a consistent supply of the ingredients on which Comfort is based.

Abattis plans to launch Comfort on Cyber Monday (November 26th, 2018) through its wholly-owned natural product management subsidiary – Vergence Naturals. Vergence is already regarded as a leader in the supply, sourcing, and promotion of naturally-inspired health and beauty brands for the conventional and cannabinoid-enhanced markets. The marketing campaign for Comfort will draw public attention to the benefits of phytocannabinoids, especially in pain management.

Arriving in just over a month after the full legalization of cannabis across the country, this will be the first Cyber Monday in which Canadians will be able to legally purchase products containing THC and/or CBD online, so it’s likely this Cyber Monday will once again set records.

 
Beyond Comfort

The release of Comfort will round out a busy year for Abattis Bioceuticals, which has advanced an ambitious business plan focused well beyond flower production and cultivation to the in-house research, development, marketing, and distribution of high-margin, high-growth cannabis-derived products.

Along with the construction of a 26,000 square foot production & extraction facility in British Columbia for its wholly-owned subsidiary, Gabriola Green Farms. Abattis has also partnered with XLABS Therapeutics to open a new 10,000 square foot cannabis laboratory in Belleville, Ontario (with an additional 310,000 square feet available for future expansion) to service the growing cannabis sector. The new production facility will allow Abattis to control its own raw material production. This is important from a financial perspective, product development perspective and quality control standpoint. The lab will give the company a strong presence on Canada’s East Coast and allow it to pursue medicinal cannabis research while offering lab services to third-parties.

Abattis is working with Northern Vine Labs to carry out R&D and analytical testing on a hemp-infused, cannabinoid-rich, THC-free craft beer in conjunction with Faculty Brewing Company. The micro-brewery is developing a variety of cannabis-based beverages in partnership with other companies. It has already developed a prototype CBD-infused sunscreen and continues work on the development of nano-emulsified and liposomal platforms for the delivery of a cannabinoid-rich hemp oil in collaboration with the University of British Columbia.

The legalization of cannabis in Canada is expected to see consumers moving away from smoking flower and toward vaping, sublinguals, creams, and oils – as other regions have experienced following legalization. Abattis is well-placed to provide a variety of alternatives, through its wholly-owned subsidiary – Green Tree Therapeutics.

The company has introduced three industry-benchmarked, Abattis branded vaporizers, and as a result will be able to load the line with its own cannabinoid formulations and retail them directly through its diverse distribution channels. Abattis vaporizers feature a 510-thread battery that can be used with any third-party cartridge.

Many of these product areas are still in their infancy, but with legalization here, cannabis research will become more efficient and cost-effective, paving the way for even greater innovation.

 
Disclaimer
 
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

FULL DISCLOSURE: Abattis Bioceuticals is a paid client of Stockhouse Publishing.



Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Healthcare
Technology
Metals & Mining
Technology
Industrials

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.